SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

Size: px
Start display at page:

Download "SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy"

Transcription

1 SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to ethanol-water extract of Caralluma fimbriata (Slimaluma ) and helps to reduce waist circumference pursuant to Article 13(5) of Regulation (EC) No 1924/ EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3 European Food Safety Authority (EFSA), Parma, Italy This scientific output, published on 18 May 2010, replaces the earlier version published on 12 May ABSTRACT Following an application from Gencor Pacific Inc. submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of United Kingdom, the Panel on Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related to ethanolwater extract of Caralluma fimbriata (Slimaluma ) and helps to reduce waist circumference. Slimaluma is an ethanol-water extract of Caralluma fimbriata standardised by its content in pregnane glycosides that is sufficiently characterised. The Panel considers that a reduction in waist circumference, if accompanied by improvement in adverse health effects of an excess abdominal fat, is a beneficial physiological effect. One human intervention provided reported a statistically significant effect of ethanol-water extract of Caralluma fimbriata on the reduction of waist circumference in humans compared to a suitable control. No significant differences in body weight, body fat, blood glucose or lipid profiles were observed over time between the two groups. In weighing the evidence, the Panel took into account that whilst waist circumference was significantly reduced in the experimental group compared to placebo after 60 days of intervention in one of the human studies presented assessing this outcome, no significant effect of the ethanol-water extract of Caralluma fimbriata on waist circumference leading to an improvement in adverse health effects associated with an excess abdominal fat was observed when compared to a suitable control. The Panel concludes that a cause and effect relationship has not 1 On request from Gencor Pacific Inc., Question No EFSA-Q , adopted on 30 April Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 3 Acknowledgement: The Panel wishes to thank Joanne A. Harrold and the members of the Working Group on Claims for the preparatory work on this opinion: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. 4 After publication of this opinion, the applicant notified to EFSA that changes in waist circumference between the intervention and placebo groups in the study by Kuriyan et al. (2007) had been erroneously reported in the opinion as statistically non significant, while these changes are significant. The opinion has been changed accordingly. This change does not affect the conclusions of the opinion as reducing waist circumference is not a beneficial physiological effect per se, but only if accompanied by an improvement in adverse health effects associated with an excess abdominal fat. In this context section 2 has been modified to indicate more clearly this fact. Where changes have been made to the opinion footnotes have been included to indicate the original text. Suggested citation: EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to ethanol-water extract of Caralluma fimbriata (Slimaluma ) and helps to reduce waist circumference pursuant to Article 13(5) of Regulation (EC) No 1924/ [11 pp.]. doi: /j.efsa Available online: European Food Safety Authority,

2 been established between the consumption of the ethanol-water extract of Caralluma fimbriata Slimaluma and a reduction in waist circumference leading to an improvement in adverse health effects associated with an excess abdominal fat. KEY WORDS Slimaluma, Caralluma fimbriata, pregnane glycosides, waist circumference, health claims. SUMMARY Following an application from Gencor Pacific Inc. submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of United Kingdom, the Panel on Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related to ethanol-water extract of Caralluma fimbriata (Slimaluma ) and helps to reduce waist circumference. The scope of the application was proposed to fall under a health claim based on newly developed scientific evidence. The food constituent that is the subject of the health claim is an ethanol-water extract of Caralluma fimbriata (Slimaluma. The ethanol-water extract of the aerial parts of Caralluma fimbriata is the source of the ingredients in Slimaluma claimed as active by the applicant. The specific extraction and subsequent manufacturing processes are specified for the content of pregnane glycosides (at least 25 % by weight), which are claimed by the applicant to be the active ingredients for appetite control, of saponin glycosides (at least 10 % by weight) and of bitters (at least 3 % by weight). The Panel considers that the food constituent, ethanol-water extract of Caralluma fimbriata (Slimaluma ), which is the subject of the health claim, is sufficiently characterised. The claimed effect is helps to reduce waist circumference. The target population is overweight adults (i.e., 18 years of age). The Panel considers that the reduction in waist circumference, if accompanied by improvement in adverse health effects of an excess abdominal fat, is a beneficial physiological effect 5. Thirteen publications were identified by the applicant as being pertinent to the claim. The references provided included in vitro studies, intervention studies and reviews on the relationship between waist circumference and cardiovascular events, the reliability and validity of Visual Analogue Scales for the assessment of appetite, the central control of body weight and appetite, the link between leptin and obesity, the impact of soluble fibres or multivitamin and mineral supplements on body weight and mitotic clonal expansion. The Panel considers that no conclusions can be drawn from these references for the substantiation of the claimed effect. Among the publications submitted, two published human intervention studies reporting on measures of waist circumference, an unpublished animal study and an unpublished in vitro study investigated the effects of ethanol-water extract of Caralluma fimbriata. The first human study was a double blind, placebo controlled, randomised intervention in 62 healthy overweight and obese volunteers. The experimental group received 1 g of ethanol-water extract of Caralluma fimbriata per day for 60 days whilst the placebo group received maltodextrin capsules. At baseline and at the end of 30 and 60 days of intervention anthropometric measurements, including waist circumference, were obtained. Body weight, body fat, fasting blood glucose and lipid profiles (triglyceride, total and HDL cholesterol) were also measured at the same time points. A statistically 5 Original text: The Panel considers that the reduction in waist circumference might be a beneficial physiological effect. 2

3 significant reduction in waist circumference was observed in the intervention group compared to placebo at the end of study. No significant differences in body weight, body fat, blood glucose or lipid profiles were observed over time between the two groups. The Panel notes that the reduction in waist circumference observed in the intervention group compared to placebo was not associated to a reduction in body fat and did not lead to an improvement in adverse health effects associated with an excess abdominal fat (e.g., a reduction in blood glucose and/or an improvement in the lipid profile) 6. The second human study was a placebo-controlled, randomised intervention in 26 overweight volunteers. The experimental group received one 500 mg capsule of ethanol-water extract of Caralluma fimbriata 30 minutes before each meal for four weeks. The nature of the placebo was not specified. Thirteen subjects in the experimental group reduced their waist circumference compared to baseline. The impact of the intervention on the waist circumference of participants in the placebo group was not reported. It is also not reported whether the reductions in waist circumference observed in the experimental group reached statistical significance when compared to the placebo group. The Panel did not receive any further clarification from the applicant on this point. The Panel considers that no conclusions can be drawn from this study for the scientific substantiation of the claimed effect. The Panel considers that the results from the animal study and the one in vitro study do not predict an effect of the ethanol-water extract of Caralluma fimbriata Slimaluma on a reduction of waist circumference in humans. In weighing the evidence, the Panel took into account that whilst waist circumference was significantly reduced in the experimental group compared to placebo after 60 days of intervention in one of the human studies presented assessing this outcome, no significant effect of the ethanol-water extract of Caralluma fimbriata on waist circumference leading to an improvement in adverse health effects associated with an excess abdominal fat was observed when compared to a suitable control 7. The Panel concludes that a cause and effect relationship has not been established between the consumption of the ethanol-water extract of Caralluma fimbriata Slimaluma and a reduction in waist circumference leading to an improvement in adverse health effects associated with an excess abdominal fat 8. 6 Original text: No significant differences in waist circumference were observed between the two groups over the duration of the study. No significant differences in blood glucose or lipid profiles were observed over time between the two groups. 7 Original text: In weighing the evidence, the Panel took into account that in the one human study assessing changes in waist circumference no significant effect of the ethanol-water extract of Caralluma fimbriata on waist circumference was observed when compared to a suitable control. 8 Original text: The Panel concludes that a cause and effect relationship has not been established between the consumption of the ethanol-water extract of Caralluma fimbriata Slimaluma and a reduction in waist circumference. 3

4 TABLE OF CONTENTS Abstract... 1 Summary... 2 Table of contents... 4 Background as provided by the European Commission... 5 Terms of reference as provided by the European Commission... 5 Information provided by the applicant... 7 Assessment Characterisation of the food/constituent Relevance of the claimed effect to human health Scientific substantiation of the claimed effect... 8 Conclusions Documentation provided to EFSA References Glossary / Abbreviations

5 BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION Regulation (EC) No 1924/ harmonises the provisions that relate to nutrition and health claims and establishes rules governing the Community authorisation of health claims made on foods. As a rule, health claims are prohibited unless they comply with the general and specific requirements of that Regulation and are authorised in accordance with this Regulation and included in the lists of authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of that Regulation lays down provisions for addition of claims (other than those referring to the reduction of disease risk and to children s development and health), which are based on newly developed scientific evidence or include a request for the protection of proprietary data, to the Community list of permitted claims referred to in Article 13(3). According to Article 18 of that Regulation, an application for inclusion in the Community list of permitted claims referred to in Art 13(3) shall be submitted by the applicant to the national competent authority of a Member State, who will make the application and any supplementary information supplied by the applicant available to the European Food Safety Authority (EFSA). STEPS TAKEN BY EFSA: The application was received on 12/01/2010. The scope of the application was proposed to fall under a health claim based on newly developed scientific evidence. The scientific evaluation procedure started on 20/01/2010. On 26/03/2010, the NDA Panel agreed on the List of Questions which requests the applicant to supplement additional particulars to accompany the application. The applicant submitted the responses to the NDA Panel List of Questions on 13/04/2010. During the meeting on 30/04/2010, the NDA Panel, after having evaluated the overall data submitted, adopted an opinion on the scientific substantiation of a health claim related to ethanol-water extract of Caralluma fimbriata (Slimaluma ) and helps to reduce waist circumference. TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion on the scientific substantiation of a health claim related to: ethanol-water extract of Caralluma fimbriata (Slimaluma ) and helps to reduce waist circumference. EFSA Disclaimer The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing of ethanol-water extract of Caralluma fimbriata (Slimaluma ), a positive assessment of its safety, nor a decision on whether ethanol-water extract of Caralluma fimbriata (Slimaluma ) is, or is not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the framework of Regulation (EC) No 1924/ European Parliament and Council (2006). Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods. Official Journal of the European Union OJ L 404, Corrigendum OJ L 12, , p

6 It should also be highlighted that the scope, the proposed wording of the claim and the conditions of use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation procedure foreseen in Article 18(4) of Regulation (EC) No 1924/

7 INFORMATION PROVIDED BY THE APPLICANT Applicant s name and address: Gencor Pacific Inc, 301 Kam On Building, 176A Queen s Road, Central, (Hong Kong). Food/constituent as stated by the applicant Ethanol-water extract of Caralluma fimbriata (Slimaluma ). Health relationship as claimed by the applicant Slimaluma is specified for the content of pregnane glycosides. According to in vitro and in vivo studies, these active ingredients act on two levels by blocking the growth of pre-adipocytes and reducing the level of leptin. These immature cells are the source of adipocytes which absorb fat and produce leptin, a hormone involved in the long-term regulation of bodyweight. High levels of leptin are found in overweight and obese people. In human trials, these observed in vivo effects translate into a significant reduction in the feelings of hunger and a reduction in the waist circumference of overweight people who consume Slimaluma as part of a healthier lifestyle. Wording of the health claim as proposed by the applicant Slimaluma helps reduce waist circumference. Specific conditions of use as proposed by the applicant The target population are people who are overweight and aged 18 years old and over. According to the applicant, the quantity of the food/constituent and pattern of consumption required to obtain the claim comprises 500 mg of Slimaluma to be taken 1 hour prior to consuming a main meal (lunch and dinner). ASSESSMENT 1. Characterisation of the food/constituent The food constituent which is the subject of the health claim is ethanol-water extract of Caralluma fimbriata (Slimaluma ). The ethanol-water extract of the aerial parts of Caralluma fimbriata is the source of the ingredients in Slimaluma claimed as active by the applicant. The specific extraction and subsequent manufacturing processes are described in detail and are specified for the content of pregnane glycosides (at least 25 % by weight), which are claimed by the applicant to be the active ingredients for appetite control, of saponin glycosides (at least 10 % by weight) and of bitters (at least 3 % by weight). Pregnane glycosides are plant steroids which are common to all the Caralluma genus and various congeners are found in all Caralluma species. The key pregnane glycosides in Caralluma fimbriata extract are caratuberside A, caratuberside B and various congeners of bouceroside. Pregnane glycosides can be separated, identified and quantified by established methods (HPLC). 7

8 The Panel considers that the food constituent, ethanol-water extract of Caralluma fimbriata (Slimaluma ), which is the subject of the health claim, is sufficiently characterised. 2. Relevance of the claimed effect to human health The claimed effect is helps to reduce waist circumference. The target population is overweight adults (i.e., 18 years of age). A reduction in waist circumference may result from a reduction in abdominal fat and/or a reduction in body water. If associated with a reduction in abdominal fat, a reduction in waist circumference may lead to an improvement in adverse health effects of an excess abdominal fat, and particularly visceral fat (e.g. improved blood glucose control, blood lipid profile). However, a reduction in waist circumference owing to a reduction in body water is not associated with such effects 10. The Panel considers that the reduction in waist circumference, if accompanied by improvement in adverse health effects of an excess abdominal fat, is a beneficial physiological effect Scientific substantiation of the claimed effect The applicant reported to have conducted a literature search in PubMed for articles published in the English language between 1970 and 2009 without restriction to population subgroup or study type using the following search terms: Caralluma, pregnane glycosides, steroid glycosides, appetite, satiety, food intake, food consumption, weight loss, weight control, diet, waist size, waist circumference and anthropometry. A total of 13 publications were included in the application for the scientific substantiation of the health claim. The references provided included in vitro studies, intervention studies and reviews on the relationship between waist circumference and cardiovascular events, the reliability and validity of Visual Analogue Scales for the assessment of appetite, the central control of body weight and appetite, the link between leptin and obesity, the impact of soluble fibres or multivitamin and mineral supplements on body weight and mitotic clonal expansion. The Panel considers that no conclusions can be drawn from these references for the substantiation of the claimed effect. Among the publications submitted, two published human intervention studies (Kuriyan et al., 2007; Lawrence and Choudhary, 2004), an unpublished animal study (Kamalakkannan, unpublished, a) and an unpublished in vitro study (Kamalakkannan, unpublished, b) investigated the effects of ethanolwater extract of Caralluma fimbriata on different outcomes. The two human intervention studies reported on measures of waist circumference. Kuriyan et al. (2007) conducted a double blind, placebo controlled, randomised intervention in 62 (23 male and 39 female) healthy overweight and obese (BMI > 25 kg/m 2 ) Indian volunteers aged between 25 and 60 years. The 50 subjects who completed the trial were evenly distributed between experimental and placebo groups. The experimental group received 1 g of ethanol-water extract of Caralluma fimbriata per day for 60 days (in the form of two 500 mg capsules) whilst the placebo group received maltodextrin capsules (two 500 mg capsules). All subjects were also provided with the same standard advice regarding diet and physical activity targeted to achieve a weight loss of 5-10 % body weight over the study period. At baseline and at the end of 30 and 60 days of intervention anthropometric measurements, including waist circumference, were obtained. Body weight, body fat, 10 Original text: The reduction in waist circumference may lead to an improvement in the adverse health effects of an excess abdominal fat, and particularly visceral fat. However, a reduction in waist circumference owing to a reduction in body water is not considered per se as a beneficial physiological effect. 11 Original text: The Panel considers that the reduction in waist circumference might be a beneficial physiological effect. 8

9 fasting blood glucose and lipid profiles (triglyceride, total and HDL cholesterol) were also measured at the same time points. A statistically significant reduction in waist circumference was observed in the intervention group compared to placebo at the end of study. No significant differences in body weight, body fat, blood glucose or lipid profiles were observed over time between the two groups. The Panel notes that the reduction in waist circumference observed in the intervention group compared to placebo was not associated with a reduction in body fat and did not lead to an improvement in adverse health effects associated with an excess abdominal fat (e.g., a reduction in blood glucose and/or an improvement in the blood lipid profile) 12. Lawrence and Choudhary (2004) conducted a placebo controlled, randomised intervention in 26 (9 males) overweight volunteers aged between 31 and 73 years. Nineteen subjects were assigned to the active group and seven to the placebo group. Twenty four subjects completed the trial; each group had one drop out. The experimental group received one 500 mg capsule of ethanol-water extract of Caralluma fimbriata 30 minutes before each meal for four weeks. The nature of the placebo was not specified. All subjects were instructed not to change their daily activity or pattern of food intake over the period of the study. They were also informed not to change their diet in any way from four weeks preceding the study. Waist circumference was measured at baseline and at the end of four weeks of intervention. The impact of the intervention on the waist circumference of participants in the placebo group was not reported. It is also not reported whether the reduction in waist circumference observed in the experimental group reached statistical significance when compared to the placebo group. The Panel did not receive any further clarification from the applicant on this point. The Panel considers that no conclusions can be drawn from this study for the scientific substantiation of the claimed effect. One intervention study on rats (Kamalakkannan et al., unpublished, a) investigating the effects of different doses (5, 10, and 20 mg/d) of an ethanol-water extract of Caralluma fimbriata containing 25 % pregnane glycosides in the context of a cafeteria diet for 90 days on feed intake, body weight, serum leptin and atheromatous plaque formation, and one in vitro study (Kamalakkannan et al., unpublished, b) investigating the effects of Slimaluma on pre-adipocyte cell division were also presented. The Panel considers that the results from these studies do not predict an effect of the ethanol-water extract of Caralluma fimbriata Slimaluma on a reduction of waist circumference in humans. In weighing the evidence, the Panel took into account that whilst waist circumference was significantly reduced in the experimental group compared to placebo after 60 days of intervention in one of the human studies presented assessing this outcome, no significant effect of the ethanol-water extract of Caralluma fimbriata on waist circumference leading to an improvement in adverse health effects associated with an excess abdominal fat was observed when compared to a suitable control 13. The Panel concludes that a cause and effect relationship has not been established between the consumption of the ethanol-water extract of Caralluma fimbriata Slimaluma and a reduction in waist circumference leading to an improvement in adverse health effects associated with an excess abdominal fat Original text: No significant differences in waist circumference were observed between the two groups over the duration of the study. No significant differences in blood glucose or lipid profiles were observed over time between the two groups. 13 Original text: In weighing the evidence, the Panel took into account that in the one human study assessing changes in waist circumference no significant effect of the ethanol-water extract of Caralluma fimbriata on waist circumference was observed when compared to a suitable control. 14 Original text: The Panel concludes that a cause and effect relationship has not been established between the consumption of the ethanol-water extract of Caralluma fimbriata Slimaluma and a reduction in waist circumference. 9

10 CONCLUSIONS On the basis of the data presented, the Panel concludes that: The food constituent, ethanol-water extract of Caralluma fimbriata (Slimaluma, which is the subject of the health claim, is sufficiently characterised. The claimed effect is helps to reduce waist circumference. The target population is overweight adults (i.e., 18 years of age). The reduction in waist circumference, if accompanied by improvement in adverse health effects of an excess abdominal fat, is a beneficial physiological effect 15. A cause and effect relationship has not been established between the consumption of ethanolwater extract of the Caralluma fimbriata Slimaluma and a reduction in waist circumference leading to an improvement in adverse health effects associated with an excess abdominal fat 16. DOCUMENTATION PROVIDED TO EFSA Health claim application on ethanol-water extract of Caralluma fimbriata (Slimaluma ) and helps to reduce waist circumference pursuant to Article or 13(5) of Regulation (EC) No 1924/2006 (Claim Serial No: 0266_UK). January Submitted by Gencor Pacific Inc. REFERENCES Kamalakkannan S, Rajendran R, Venkatesh RV and Akbarsha MA, unpublished, a. Anti-Obesegenic and Anti-Atherosclerotic Property of Caralluma fimbriata Extract. Kamalakkannan S, Rajendran R, Venkatesh RV and Akbarsha MA, unpublished, b. Effect of Caralluma fimbriata extract on 3T3-L1 pre-adipocyte cell division. Kuriyan R, Raj T, Srinivas SK, Vaz M, Rajendran R and Kurpad AV, Effect of Caralluma fimbriata extract on appetite, food intake and anthropometry in adult Indian men and women. Appetite, 48, Lawrence RM and Choudhary S, Caralluma Fimbriata in the treatment of obesity. 12th Annual World Congress of Anti-Aging Medicine, December, Las Vegas, USA. 15 Original text: The claimed effect is helps to reduce waist circumference. The target population is overweight adults (i.e., 18 years of age). The reduction in waist circumference might be a beneficial physiological effect. 16 Original text: A cause and effect relationship has not been established between the consumption of ethanol-water extract of the Caralluma fimbriata Slimaluma and a reduction in waist circumference. 10

11 GLOSSARY / ABBREVIATIONS BMI Body mass index HPLC LDL High performance liquid chromatography Low-density lipoproteins 11

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to ethanol-water extract of Caralluma fimbriata (Slimaluma ) and helps to control hunger/appetite pursuant to Article

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to zinc and the prevention of bad breath by neutralising of volatile sulphur compounds in the mouth and oral cavity

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3 SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to calcium-containing fruit juices and the reduction of tooth demineralisation pursuant to Article 14 of Regulation

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to Immune Balance Drink and strengthening body s defences pursuant to Article 13(5) of Regulation (EC) No 1924/2006

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy EFSA Journal 2011;9(4):2130 SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to alpha-linolenic acid and contribution to brain and nerve tissue development pursuant

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to hyaluronic acid and protection of the skin against dehydration pursuant to Article 13(5) of Regulation (EC) No 1924/2006

More information

EFSA Publication; Tetens, Inge. Link to article, DOI: /j.efsa Publication date: 2011

EFSA Publication; Tetens, Inge. Link to article, DOI: /j.efsa Publication date: 2011 Downloaded from orbit.dtu.dk on: Jan 08, 2019 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to zinc and the prevention

More information

Scientific Opinion on the substantiation of a health claim related to a combination of thiamin, riboflavin, niacin, pantothenic acid, pyridoxine,

Scientific Opinion on the substantiation of a health claim related to a combination of thiamin, riboflavin, niacin, pantothenic acid, pyridoxine, SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to a combination of thiamin, riboflavin, niacin, pantothenic acid, pyridoxine, D-biotin and pumpkin seed oil and maintenance

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to Opti EFAX and maintenance of normal blood LDL-cholesterol concentrations pursuant to Article 13(5) of Regulation

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy EFSA Journal 2012;10(5):2697 SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to glucose and contribution to energy-yielding metabolism pursuant to Article 13(5) of

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to honey and respiratory health through presence of antioxidant phytochemicals (ID 1161), the unique composition and

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy EFSA Journal 2012;10(12):2999 SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to OXY 280 and reduction of body weight pursuant to Article 13(5) of Regulation (EC)

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to ribose and faster recovery from muscle fatigue after exercise (ID 4226) pursuant to Article 13(1) of Regulation (EC)

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to L-carnosine and increase in muscle power (ID 1824), increase in endurance capacity (ID 1824), skin (ID 1825) and

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to L-ornithine and contribution to the regulation of the urea cycle (ID 4270) pursuant to Article 13(1) of Regulation

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to spermidine and prolongation of the growing phase (anagen) of the hair cycle pursuant to Article 13(5) of Regulation

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy EFSA Journal 2011;9(6):2210 SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to capsaicin and maintenance of body weight after weight loss (ID 2039, 2041, 2042), increase

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2,3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2,3. European Food Safety Authority (EFSA), Parma, Italy EFSA Journal 2015;13(5):4096 SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to vitamin D and contribution to the normal function of the immune system pursuant to

More information

SCIENTIFIC OPINION. Lipil and brain development

SCIENTIFIC OPINION. Lipil and brain development The EFSA Journal (2009) 1001, 1-8 SCIENTIFIC OPINION Lipil and brain development Scientific substantiation of a health claim related to Lipil and brain development pursuant to Article14 of Regulation (EC)

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2,3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2,3. European Food Safety Authority (EFSA), Parma, Italy EFSA Journal 2015;13(2):4027 SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to glycaemic carbohydrates and contribution to normal cognitive function pursuant to Article

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to thiamine and carbohydrate and energy-yielding metabolism pursuant to Article 14 of Regulation (EC) No 1924/2006

More information

SCIENTIFIC OPINION. Scientific Opinion of the Panel on Dietetic Products, Nutrition and Allergies. (Question No EFSA-Q )

SCIENTIFIC OPINION. Scientific Opinion of the Panel on Dietetic Products, Nutrition and Allergies. (Question No EFSA-Q ) The EFSA Journal (2009) 1004, 1-8 SCIENTIFIC OPINION Enfamil Premium and visual development Scientific substantiation of a health claim related to Enfamil Premium and visual development pursuant to Article14

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to mesozeaxanthin and maintenance of vision (ID 2096) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 1 EFSA

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to n-3 polyunsaturated fatty acids (n-3 PUFAs) and nutrient tasks and interactions (ID 574), increase in calcium absorption

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to monomeric flavan-3-ols from apples and improvement of endotheliumdependent vasodilation (ID 1936) pursuant to Article

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2,3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2,3. European Food Safety Authority (EFSA), Parma, Italy EFSA Journal 2014;12(5):3652 SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to complex carbohydrates and contribute to satiety pursuant to Article 14 of Regulation

More information

Statement on toothkind juice drinks 1

Statement on toothkind juice drinks 1 EFSA Journal 2011;9(7):2293 SCIENTIFIC OPINION Statement on toothkind juice drinks 1 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3 European Food Safety Authority (EFSA), Parma, Italy

More information

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on Downloaded from orbit.dtu.dk on: May 03, 2018 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of a health claim related to Rhodiola rosea L. extract

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to flavan-3-ols and vascular activity (ID 1964) and dermal activity (ID 1965) pursuant to Article 13(1) of Regulation

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3 SUMMARY. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3 SUMMARY. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to casein protein hydrolysates and growth or maintenance of muscle mass (ID 1498), increase in endurance performance

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy EFSA Journal 2012;10(12):3000 SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to a combination of Paullinia cupana Kunth (guarana) and Camellia sinensis (L.) Kuntze

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to linoleic acid and molecule precursors regulating cell functions (prostaglandins, leucotrienes) (ID 488, 4670), maintenance

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy EFSA Journal 2011;9(4):2058 SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to epigallocatechin gallate (EGCG) in combination with caffeine, and (ID 1800) pursuant

More information

SCIENTIFIC OPINION. Melgaço mineral water and reduction of glycaemia. Scientific Opinion of the Panel on Dietetic Products, Nutrition and Allergies

SCIENTIFIC OPINION. Melgaço mineral water and reduction of glycaemia. Scientific Opinion of the Panel on Dietetic Products, Nutrition and Allergies The EFSA Journal (2009) 944, 1-9 SCIENTIFIC OPINION Melgaço mineral water and reduction of glycaemia Scientific substantiation of a health claim related to Melgaço mineral water and reduction of glycaemia

More information

Niacin and contribution to normal energy-yielding metabolism: evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006

Niacin and contribution to normal energy-yielding metabolism: evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 SCIENTIFIC OPINION ADOPTED: 29 June 2015 PUBLISHED: 17 July 2015 doi:10.2903/j.efsa.2015.4180 Niacin and contribution to normal energy-yielding metabolism: evaluation of a health claim pursuant to Article

More information

SCIENTIFIC OPINION. (Question No EFSA-Q ) Adopted on 15 May 2009

SCIENTIFIC OPINION. (Question No EFSA-Q ) Adopted on 15 May 2009 The EFSA Journal (2009) 1106, 1-8 SCIENTIFIC OPINION Bimuno TM and support of the immune system Scientific substantiation of a health claim related to Bimuno TM and support of the immune system pursuant

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to thiamin and reduction of tiredness and fatigue (ID 23) and contribution to normal psychological functions (ID 205)

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to a combination of lycopene, vitamin E, lutein and selenium and helps to prepare and activate tanning pursuant to

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to linoleic acid and maintenance of neurological function (ID 732, 2897) pursuant to Article 13(1) of Regulation (EC)

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to hypo-caloric snacks (KOT products) and contributes to reduce adipocyte size at the pursuant to Article 13(5) of

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to pantothenic acid and mental performance (ID 58), reduction of tiredness and fatigue (ID 63), adrenal function (ID

More information

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2014.

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2014. Downloaded from orbit.dtu.dk on: Sep 12, 2018 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2014. Scientific Opinion on the substantiation of a health claim related to DHA

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to adenosine triphosphate (ATP) and maintenance of normal muscle function (ID 1946) pursuant to Article 13(1) of Regulation

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to betaine and contribution to normal homocysteine metabolism (ID 4325) pursuant to Article 13(1) of Regulation (EC)

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to echium oil and maintenance of normal blood concentrations of triglycerides (ID 548) pursuant to Article 13(1) of

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to fermented whey and gut health (ID 1803) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 1 EFSA Panel on

More information

SCIENTIFIC OPINION. white Swiss chard and protection of blood lipids from oxidative damage.

SCIENTIFIC OPINION. white Swiss chard and protection of blood lipids from oxidative damage. SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to a combination of red spinach, green spinach, red chicory, green chicory, green leaf chard, red leaf chard, red Swiss

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy EFSA Journal 2012;10(12):2997 SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to Vitis vinifera L. seeds extract and helps to decrease swollen legs pursuant to Article

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to gammaaminobutyric acid and cognitive function (ID 1768) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

More information

SCIENTIFIC OPINION. Kinder Chocolate and growth

SCIENTIFIC OPINION. Kinder Chocolate and growth The EFSA Journal (2009) 940, 1-8 SCIENTIFIC OPINION Kinder Chocolate and growth Scientific substantiation of a health claim related to Kinder Chocolate and growth pursuant to Article 14 of Regulation (EC)

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to eicosapentaenoic acid (EPA) and enhancement of mood (ID 633), calming (ID 634), increased attention (ID 634), increase

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to Lactobacillus paracasei LPC 01 (CNCM I-1390) and treatment of disease (ID 3055, further assessment) pursuant to Article

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to a C12-peptide (Phe-Phe-Val-Ala-Pro-Phe-Pro-Glu-Val-Phe-Gly-Lys) and maintenance of normal blood pressure (ID 1483,

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to Eff EXT and helps to support joint function by maintaining low levels of plasma C-reactive protein pursuant to Article

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to Lactobacillus reuteri ATCC 55730 and natural defence (ID 905) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to linoleic acid (LA) in combination with gamma-linolenic acid (GLA) and reduction of ocular dryness (ID 4274) pursuant

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to maize oil and maintenance of normal blood LDL-cholesterol concentrations (ID 3086) pursuant to Article 13(1) of Regulation

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to fats and function of the cell membrane (ID 622, 2900, 2911) and normal absorption of fat-soluble vitamins (ID 670,

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to iron and maintenance of normal hair growth pursuant to Article 13(5) of Regulation (EC) No 1924/2006 1 EFSA Panel

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to Catalgine bouffées de chaleur and contributes to the reduction in the number of hot flushes pursuant to Article

More information

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on Downloaded from orbit.dtu.dk on: Sep 13, 2018 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to foods with reduced lactose

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to caffeine and theobromine in cocoa (Theobroma cacao L.) and enhancement of mood (ID 4276) pursuant to Article 13(1)

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to isomalto-oligosaccharides and reduction of post-prandial glycaemic responses (ID 798), and increase in the frequency

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to shark cartilage and maintenance of joints (ID 1852, 1853) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to vitamin A (including β-carotene) and maintenance of normal vision (ID 4239, 4701), maintenance of normal skin and

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to creatine and increased attention (ID 1524) and improvement of memory (ID 1528) pursuant to Article 13(1) of Regulation

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy EFSA Journal 2011;9(12):2467 SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to sugar beet fibre and decreasing intestinal transit time pursuant to Article 13(5) of

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to alpha-cylcodextrin and reduction of post-prandial glycaemic responses (ID 856, 2926), maintenance or achievement

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to water and maintenance of normal physical and cognitive functions (ID 1102, 1209, 1294, 1331), maintenance of normal

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to L-phenylalanine and increased alertness (ID 708, 1629), enhancement of mood (ID 657), pain relief (ID 657) and improvement

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to glycaemic carbohydrates and maintenance of normal brain function (ID 603, 653) pursuant to Article 13(1) of Regulation

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to gamma-linolenic acid and reduction of inflammation (ID 1772) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to acacia gum (gum arabic) and reduction of post-prandial glycaemic responses (ID 842, 1977) and maintenance of normal

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion related to a notification from Genecor International BV on barley beta-amylase from unmalted barley to be used in starch degradation to produce glucose syrups rich

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to peanuts, peanut oil and peanut butter manufactured exclusively from roasted peanuts, (ID 1284) pursuant to Article

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to pursuant to Article 13(5) of Regulation (EC) No 1924/2006 1 EFSA Panel on Dietetic Products, Nutrition and Allergies

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to foods with reduced amounts of saturated fatty acids (SFAs) and maintenance of normal blood LDL-cholesterol concentrations

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2,3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2,3. European Food Safety Authority (EFSA), Parma, Italy EFSA Journal 2014;12(11):3892 SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to prunes and contribution to normal bowel function pursuant to Article 14 of Regulation

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy EFSA Journal 2010; 8(10):1802 SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to Lactobacillus fermentum CECT5716 and maintenance of the upper respiratory tract defence

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to beta-alanine and increase in physical performance during short-term high-intensity exercise (ID 436, 1453, 1454,

More information

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on Downloaded from orbit.dtu.dk on: Sep 04, 2018 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to alpha-lipoic acid and

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to stearic acid and maintenance of normal blood cholesterol concentrations (ID 716, 1657) pursuant to Article 13(1)

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to acetyl-l-carnitine and contribution to normal cognitive function (ID 1432) pursuant to Article 13(1) of Regulation

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy EFSA Journal 2010;8(10):1797 SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to fluoride and maintenance of tooth mineralisation (ID 338, 4238) pursuant to Article

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy EFSA Journal 2013;11(10):3411 SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to pantothenic acid and contribution to normal energy-yielding metabolism pursuant to

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to acacia gum and maintenance of normal blood cholesterol concentrations (ID 1976) pursuant to Article 13(1) of Regulation

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2,3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2,3. European Food Safety Authority (EFSA), Parma, Italy EFSA Journal 2014;12(5):3654 SCIENTIFIC OPINION Scientific Opinion on the modification of the authorisation of a health claim related to cocoa flavanols and maintenance of normal endotheliumdependent vasodilation

More information

ADOPTED: 28 October 2015 PUBLISHED: 13 November 2015

ADOPTED: 28 October 2015 PUBLISHED: 13 November 2015 SCIENTIFIC OPINION ADOPTED: 28 October 2015 PUBLISHED: 13 November 2015 doi:10.2903/j.efsa.2015.4298 Vitamin C and contribution to the normal function of the immune system: evaluation of a health claim

More information

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2013.

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2013. Downloaded from orbit.dtu.dk on: Jun 16, 2018 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2013. Scientific Opinion on the substantiation of a health claim related to VeriSol

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to alpha-lipoic acid and protection of body lipids from oxidative damage (ID 1434, 3134), maintenance of normal blood

More information

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on Downloaded from orbit.dtu.dk on: Jul 10, 2018 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to docosahexaenoic acid (DHA),

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to lutein and protection of DNA, proteins and lipids from oxidative damage (ID 3427), protection of the skin from UV-induced

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to phosphatidyl serine (ID 552, 711, 734, 1632, 1927) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 1 EFSA

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to sugar beet fibre and increasing faecal bulk pursuant to Article 13(5) of Regulation (EC) No 1924/2006 1 ABSTRACT

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy EFSA Journal 2010;8(10):1743 SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to various food(s)/food constituent(s) and improved bioavailability of nutrients (ID 384,

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy EFSA Journal 2010;8(10):1757 SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to niacin and reduction of tiredness and fatigue (ID 47), contribution to normal energy-yielding

More information

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy

SCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2, 3. European Food Safety Authority (EFSA), Parma, Italy EFSA Journal 2013;11(10):3410 SCIENTIFIC OPINION Scientific Opinion on the substantiation of a health claim related to riboflavin (vitamin B2) and contribution to normal energy-yielding metabolism pursuant

More information